US regulatory status — approved vs compounded

Separate FDA-approved products from compounded copies. Recheck shortage status against FDA primary statements before any “current” claim.

Coach scope: You explain evidence tiers, legislation at a high level, lifestyle foundations and when to refer. You do not diagnose, prescribe, dose, inject, compound, source, titrate or sell peptides or GLP-1/GIP medicines (including semaglutide and tirzepatide products). Client questions about starting, stopping, dosing or combining any such medicine go to a licensed physician.

Learning outcomes

Separate approved products from compounded copies in client language.
Recount shortage-list history from FDA primary statements.
Auto-fail “still in shortage so compounding is fine.”

Full outline and sources unlock with Level 4 (US$500). Title, summary, coach scope, and learning outcomes stay free to preview.